Recent advances in management of small-cell lung cancer

Cancer Treatment Reviews

Volumn 30, Issue 6, 2004, Pages 521-543

  Chua, Yu Jo ^a   Steer, Christopher ^b,c   Yip, Desmond ^a,d  

^a CANBERRA HOSPITAL   (Australia)

^b Border Medical Oncology Australia   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d The Australian National University   (Australia)

Author keywords

Aged; Antineoplastic agents therapeutic use; Biological therapy; Carcinoma, small cell; Combined modality therapy; Drug therapy, combination; Lung neoplasms; Neoplasms, recurrence; Radiotherapy; Review

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MESNA; METHOTREXATE; PACLITAXEL; PLACEBO; PLATINUM; PLATINUM DERIVATIVE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROXITHROMYCIN; STEROID; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ALOPECIA; ANTIBIOTIC PROPHYLAXIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; HYPERSENSITIVITY REACTION; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MENTAL STRESS; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; PROGNOSIS; PROPHYLAXIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKULL IRRADIATION; SMOKING; TREATMENT OUTCOME; VOMITING;

EID: 4344564960     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.06.003     Document Type: Article

References (160)

1. Parkin D.M. Pisani P. Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990 Int. J. Cancer 80 1999 827-841
2. Pisani P. Parkin D.M. Bray F. Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990 Int. J. Cancer 83 1999 18-29
3. Janssen-Heijnen M.L. Coebergh J.W. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe Lung Cancer 31 2001 123-137
4. Ihde D.C. Pass H.I. Glatstein E.J. Small cell lung cancer Rosenberg S.A. (Ed.). Cancer: principles and practice of oncology 4th ed. 1993 723-758 JB Lippincott Philadelphia, PA
5. Khuder S.A. Mutgi A.B. Effect of smoking cessation on major histologic types of lung cancer Chest 120 2001 1577-1583
6. Videtic G.M. Stitt L.W. Dar A.R. et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival J. Clin. Oncol. 21 2003 1544-1549
7. Johnston-Early A. Cohen M.H. Minna J.D. et al. Smoking abstinence and small cell lung cancer survival. An association JAMA 244 1980 2175-2179
8. Yip D. Harper P.G. Predictive and prognostic factors in small cell lung cancer: current status Lung Cancer 28 2000 173-185
9. Rawson N.S. Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research Br. J. Cancer 61 1990 597-604 published erratum appears in Br J Cancer 1990; 62 (3):550
10. Cerny T. Blair V. Anderson H. et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients Int. J. Cancer 39 1987 146-149
11. Bremnes R.M. Sundstrom S. Aasebo U. et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up Lung Cancer 39 2003 303-313
12. Sambrook R.J. Girling D.J. A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom Br. J. Cancer 84 2001 1447-1452
13. Green R. Humphrey E. Close H. et al. Alkylating agents in bronchogenic carcinoma Am. J. Med. 46 1969 516-525
14. Bunn P. Cohen M. Ihde D.C. et al. Advances in small cell bronchogenic carcinoma Cancer Treat Rep. 61 1977 333-342
15. Aisner J. Extensive-disease small cell lung cancer: the thrill of victory; the agony of defeat J. Clin. Oncol. 12 1996 658-665
16. Pujol J.L. Carestia L. Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent Br. J. Cancer 83 2000 8-15
17. Mascaux C. Paesmans M. Berghmans T. et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis Lung Cancer 30 2000 23-36
18. Sundstrom S. Bremnes R.M. Kaasa S. et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up J. Clin. Oncol. 20 2002 4665-4672
19. Skarlos D.V. Samantas E. Kosmidis P. et al. Randomized comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study Ann. Oncol. 5 1994 601-607
20. Lassen U. Kristjansen P.E. Osterlind K. et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up Ann. Oncol. 7 1996 365-371
21. Wolf M. Havemann K. Drings P. et al. Alternating chemotherapy with doxorubicin, ifosphamide, and vincristine plus cisplatin and etoposide versus doxorubicin, ifosphamide and vincristine plus carboplatin and etoposide in small cell lung cancer Bunn P.A. Canetta R. Ozols R.F. et al. (Eds.). Carboplatin (JM8): current perspectives and future directions 1990 283-294 WB Saunders Philadelphia, PA
22. Krug L.M. Grant S.C. Miller V.A. et al. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination Semin. Oncol. 26 1999 55-61
23. Pujol J.L. Daures J.P. Riviere A. et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study J. Natl. Cancer Inst. 93 2001 300-308
24. Laskin J. Sandler A. Johnson D.H. An advance in small-cell lung cancer treatment-more or less J. Natl. Cancer Inst. 95 2003 1099-1101
25. Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996;73:406-13
26. Thatcher N. Qian W. Girling D.J. Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance (PS): Results of an MRC randomized trial (LU21) Proc. Am. Soc. Clin. Oncol. 22 2003 619a
27. Klasa R.J. Murray N. Coldman A.J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung J. Clin. Oncol. 9 1991 499-508
28. Arriagada R. Le Chevalier T. Pignon J.P. et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer N. Engl. J. Med. 329 1993 1848-1852
29. Murray N. Livingston R. Shepherd F. et al. Randomized study of CODE versus alternating CAV/PE for extensive-stage small cell lung cancer: An Intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group J. Clin. Oncol. 17 1999 2300-2308
30. Souhami R.L. Rudd R. Ruiz de Elvira M.C. et al. Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial J. Clin. Oncol. 12 1994 1806-1813
31. Sculier J.P. Paesmans M. Bureau G. et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party J. Clin. Oncol. 11 1993 1858-1865
32. Masutani M. Ochi Y. Kadota A. et al. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors? Oncol. Rep. 7 2000 305-310
33. Woll P. Thatcher N. Lomax L. et al. Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients J. Clin. Oncol. 19 2001 712-719
34. Woll P.J. Hodgetts J. Lomax L. et al. Can cytotoxic dose-intensity be increased by using granulocyte colony- stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer J. Clin. Oncol. 13 1995 652-659
35. Steward W.P. von Pawel J. Gatzemeier U. et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients J. Clin. Oncol. 16 1998 642-650
36. Thatcher N. Girling D.J. Hopwood P. et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party J. Clin. Oncol. 18 2000 395-404
37. Sculier J.P. Paesmans M. Lecomte J. et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics Br. J. Cancer 85 2001 1444-1451
38. Lorigan P. Woll P. O'Brien M. et al. Randomised phase3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) Proc. Am. Soc. Clin. Oncol. 22 2003 619a
39. Pujol J.L. Douillard J.Y. Riviere A. et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study J. Clin. Oncol. 15 1997 2082-2089
40. Ardizzoni A. Tjan-Heijnen V.C. Postmus P.E. et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923 J. Clin. Oncol. 20 2002 3947-3955
41. Tjan-Heijnen V.C. Postmus P.E. Ardizzoni A. et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study Ann. Oncol. 12 2001 1359-1368
42. Tjan-Heijnen V.C. Caleo S. Postmus P.E. et al. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923) Ann. Oncol. 14 2003 248-257
43. Elias A. Dose-intensive therapy in small cell lung cancer Chest 113 1998 101S-106S
44. Humblet Y. Symann M. Bosly A. et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study J. Clin. Oncol. 5 1987 1864-1873
45. Leyvraz S. Perey L. Rosti G. et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation J. Clin. Oncol. 17 1999 3531-3539
46. Goodman G.E. Crowley J.J. Blasko J.C. et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study J. Clin. Oncol. 8 1990 39-47
47. Postmus P.E. Scagliotti G. Groen H.J. et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial Eur. J. Cancer 32A 1996 1498-1503
48. Ueoka H. Kiura K. Tabata M. et al. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up Cancer 83 1998 283-290
49. Giaccone G. Dalesio O. McVie G.J. et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group J. Clin. Oncol. 11 1993 1230-1240
50. Bleehen N.M. Girling D.J. Machin D. et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party Br. J. Cancer 68 1993 1150-1156
51. Bleehen N.M. Girling D.J. Machin D. et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party Br. J. Cancer 68 1993 1157-1166
52. Spiro S.G. Souhami R.L. Geddes D.M. et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial Br. J. Cancer 59 1989 578-583
53. Sculier J.P. Berghmans T. Castaigne C. et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature Lung Cancer 19 1998 141-151
54. Einhorn L.H. Crawford J. Birch R. et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer J. Clin. Oncol. 6 1988 451-456
55. Beith J.M. Clarke S.J. Woods R.L. et al. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung Eur. J. Cancer 32A 1996 438-443
56. Sculier J.P. Paesmans M. Bureau G. et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party J. Clin. Oncol. 14 1996 2337-2344
57. Broder L.E. Sridhar K.S. Selawry O.S. et al. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification Am. J. Clin. Oncol. 17 1994 527-537
58. Schiller J.H. Adak S. Cella D. et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 2114-2122
59. Huisman C. Postmus P.E. Giaccone G. et al. Second-line chemotherapy and its evaluation in small cell lung cancer Cancer Treat Rev. 25 1999 199-206
60. Shepherd F.A. Evans W.K. MacCormick R. et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer Cancer Treat Rep. 71 1987 941-944
61. Sculier J.P. Klastersky J. Libert P. et al. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer[letter] Eur. J. Cancer 26 1990 919-921
62. von Pawel J. Schiller J.H. Shepherd F.A. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J. Clin. Oncol. 17 1999 658-667
63. von Pawel J. Gatzemeier U. Pujol J.L. et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer J. Clin. Oncol. 19 2001 1743-1749
64. Eckardt J.R. von Pawel J. Papai Z. et al. A meta-analysis of efficacy data from two randomised studies on oral topotecan in patients with relapsed SCLC Eur. J. Cancer 1 2003 S237
65. Eckardt J.R. Von Pawel J. Hainsworth J.D. et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study Proc. Am. Soc. Clin. Oncol. 22 2003 619a
66. Dajczman E. Fu L.Y. Small D. et al. Treatment of small cell lung carcinoma in the elderly Cancer 77 1996 2032-2038
67. Shepherd F.A. Amdemichael E. Evans W.K. et al. Treatment of small cell lung cancer in the elderly J. Am. Geriatr. Soc. 42 1994 64-70
68. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Lancet 1996;348:563-66
69. Souhami R.L. Spiro S.G. Rudd R.M. et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy J. Natl. Cancer Inst. 89 1997 577-580
70. Westeel V. Murray N. Gelmon K. et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen J. Clin. Oncol. 16 1998 1940-1947
71. Noda K. Nishiwaki Y. Kawahara M. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N. Engl. J. Med. 346 2002 85-91
72. Sandler A. Langer C. Bunn P.A. et al. Interim safety analysis of irinotecan and cisplatin combination chemotherapy for previously untreated extensive small cell lung cancer Proc. Am. Soc. Clin. Oncol. 22 2003 631a
73. Yokoyama A. Kurita Y. Saijo N. et al. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer Br. J. Cancer 78 1998 257-262 see comments
74. Ettinger D.S. Finkelstein D.M. Sarma R.P. et al. Phase II study of paclitaxel in patients with extensive-disease small- cell lung cancer: an Eastern Cooperative Oncology Group study J. Clin. Oncol. 13 1995 1430-1435
75. Smit E.F. Fokkema E. Biesma B. et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer Br. J. Cancer 77 1998 347-351
76. Mavroudis D. Papadakis E. Veslemes M. et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer Ann. Oncol. 12 2001 463-470
77. Niell H.B. Herndon J.E. Miller A.A. et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) Proc. Am. Soc. Clin. Oncol. 21 2002 293a
78. Kelly K. Lovato L. Bunn P.A. Jr. et al. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group Clin. Cancer Res. 7 2001 2325-2359
79. Reck M. von Pawel J. Macha H.N. et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer J. Natl. Cancer Inst. 95 2003 1118-1127
80. Kakolyris S. Mavroudis D. Tsavaris N. et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study Ann. Oncol. 12 2001 193-197
81. Cormier Y. Eisenhauer E. Muldal A. et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group Ann. Oncol. 5 1994 283-285
82. Van der Lee I. Postmus P. Smit E. et al. The Activity of Gemcitabine in Patients with Resistant Small Cell Lung Cancer (SCLC); a Phase II Study Proc. Am. Soc. Clin. Oncol. 18 1999 476a
83. Masters G.A. Declerck L. Blanke C. et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597 J. Clin. Oncol. 21 2003 1550-1555
84. Hoang T. Kim K. Jaslowski A. et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Lung Cancer 42 2003 97-102
85. Skarlos D.V. Dimopoulos A.M. Kosmidis P. et al. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group Lung Cancer 41 2003 107-111
86. James L.E. Rudd R.M. Gower N.H. et al. A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) Proc. Am. Soc. Clin. Oncol. 21 2002 293a
87. Pignon J.P. Arriagada R. Ihde D.C. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer N. Engl. J. Med. 327 1992 1618-1624
88. Warde P. Payne D. Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? A meta-analysis J. Clin. Oncol. 10 1992 890-895
89. Albain K.S. Crowley J.J. LeBlanc M. Livingston R.B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base J. Clin. Oncol. 8 1990 1563-1574
90. Albain K.S. Crowley J.J. Livingston R.B. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience Chest 99 1991 1425-1432
91. Jacoulet P. Depierre A. Moro D. et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise Ann. Oncol. 8 1997 1009-1014
92. Perry M.C. Eaton W.L. Propert K.J. et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung N. Engl. J. Med. 316 1987 912-918
93. Perry M.C. Herndron III J.E. Eaton W.L. et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083 J. Clin. Oncol. 16 1998 2466-2467
94. Murray N. Coy P. Pater J.L. et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 11 1993 336-344
95. Work E. Nielsen O.S. Bentzen S.M. et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group J. Clin. Oncol. 15 1997 3030-3037
96. Jeremic B. Shibamoto Y. Acimovic L. et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study J. Clin. Oncol. 15 1997 893-900
97. Skarlos D.V. Samantas E. Briassoulis E. et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG) Ann. Oncol. 12 2001 1231-1238
98. Takada M. Fukuoka M. Kawahara M. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104 J. Clin. Oncol. 20 2002 3054-3060
99. James L. Spiro S. Rudd R. et al. A randomised study of timing of thoracic irradiation in small cell lung cancer (SCLC) - study 8 Lung Cancer 41 2003 23
100. Goto K, Nishiwaki Y, Takada M, et al. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with cisplatin (P) and etoposide (E) for limited-stage small cell lung cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) Study. Proc Am Soc Clin Oncol, 1999. Vol. Abstract 1805
101. Lebeau B. Urban T. Brechot J.M. et al. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group Cancer 86 1999 1480-1487
102. Fried D.B. Morris D.E. Hensing T.A. et al. A meta-analysis evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer Int. J. Radiat. Oncol. Biol. Phys 57 2003 S139-S140
103. Humblet Y. Bosquee L. Weynants P. et al. High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells Bone Marrow Transpl. 18 Suppl 1 1996 S36-S39
104. van de Velde H. Bosquee L. Weynants P. et al. Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Universite Catholique de Louvain, Brussels and Liege, Belgium Ann. Oncol. 10 1999 1051-1057
105. Coy P. Hodson I. Payne D.G. et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial Int. J. Radiat. Oncol. Biol. Phys. 14 1988 219-226
106. De Ruysscher D. Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects Radiother. Oncol. 55 2000 1-9
107. Kies M.S. Mira J.G. Crowley J.J. et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study J. Clin. Oncol. 5 1987 592-600
108. Turrisi III A.T. Kim K. Blum R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N. Engl. J. Med. 340 1999 265-271
109. Bonner J.A. Sloan J.A. Shanahan T.G. et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma J. Clin. Oncol. 17 1999 2681-2691
110. Auperin A. Arriagada R. Pignon J.P. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group N. Engl. J. Med. 341 1999 476-484
111. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001:http://www.biomedcentral.com/1471-2407/1/5
112. Arriagada R. Le Chevalier T. Riviere A. et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients Ann. Oncol. 13 2002 748-754
113. Arriagada R. Le Chevalier T. Borie F. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission J. Natl. Cancer Inst. 87 1995 183-190
114. Gregor A. Cull A. Stephens R.J. et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC) Eur. J. Cancer 33 1997 1752-1758
115. Komaki R. Meyers C.A. Shin D.M. et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation Int. J. Radiat. Oncol. Biol. Phys. 33 1995 179-182
116. Shepherd F.A. Alternatives to chemotherapy and radiotherary in the treatment of small cell lung cancer Semin. Oncol. 28 2001 30-37
117. Mattson K. Niiranen A. Pyrhonen S. et al. Natural interferon alfa as maintenance therapy for small cell lung cancer Eur. J. Cancer 1992 1387-1391
118. Mattson K. Niiranen A. Ruotsalainen T. et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival J. Interferon Cytokine Res. 17 1997 103-105
119. Kelly K. Crowley J.J. Bunn P.A. et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study J. Clin. Oncol. 13 1995 2924-2930
120. Ruotsalainen T. Halme M. Isokangas O.P. et al. Interferon-α and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer - a feasibility study Anticancer Drugs 11 2000 101-108
121. Jett J.R. Maksymiuk A.W. Su J.Q. et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer J. Clin. Oncol. 12 1994 2321-2326
122. van Zandwijk N. Groen H.J. Postmus P.E. et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group Eur. J. Cancer 33 1997 1759-1766
123. Ruotsalainen T.M. Halme M. Tamminen K. et al. Concomitant chemotherapy and IFN-α for small cell lung cancer: a randomized multicenter phase III study J. Interferon Cytokine Res. 19 1999 253-259
124. Lee S.M. James L.E. Mohamed-Ali V. et al. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC) Proc. Am. Soc. Clin. Oncol. 21 2002 313a
125. Yip D. Ahmad A. Karapetis C.S. et al. Matrix metalloproteinase inhibitors: applications in oncology Invest. New Drugs 17 1999 387-399
126. Shepherd F.A. Giaccone G. Seymour L. et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer J. Clin. Oncol. 20 2002 4434-4439
127. Rigas J.R. Denham C.A. Rinaldi D.A. et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI) BAY 12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer Proc. Am. Soc. Clin. Oncol. 22 2003 628a
128. Sridhar S.S. Shepherd F.A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer Lung Cancer 42 2003 S81-S91
129. Shepherd F.A. Sridhar S.S. Angiogenesis inhibitors under study for the treatment of lung cancer Lung Cancer 41 2003 S63-S72
130. Wedge S.R. Ogilvie D.J. Dukes M. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res. 62 2002 4645-4655
131. Hurwitz H. Holden S.N. Eckhardt S.G. et al. Clinical evaluation of ZD6474, and orally active inhibitor of VEGF signaling, in patients with solid tumors Proc. Am. Soc. Clin. Oncol. 21 2002 82a
132. Cancer.gov. ZD6474 in treating patients with small cell lung cancer. National Cancer Institure, Bethesda 2003 [Updated 2003 October 14;cited 2004 April 12]. Available from http://www.cancer.gov/ clinicaltrials/CAN-NCIC-BR20
133. Grant S.C. Kris M.G. Houghton A.N. et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette- Guerin Clin. Cancer Res. 5 1999 1319-1323
134. Cancer.gov. Phase I/II study of autologous dendritic cell-adenovirus p53 vaccine after standard chemotherapy in patients with extensive small cell lung cancer. National Cancer Institure, Bethesda 2002 [Updated 2003 December 10; cited 2004 April 12]. Available from http://www.nci.nih.gov/ClinicalTrials/view_clinicaltrials.aspx? cdrid=257814&protocolnum=&version= healthprofessionals&protocolsearchid=874676
135. Lutzker S.G. Lattime E.C. Use of dendritic cells to immunize against cancers overexpressing p53 Clin. Cancer Res. 7 2001 2-4
136. Rudin C. Kosloff M. Edelman M. et al. Phase I study of G3139 (oblimersen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC) Proc. Am. Soc. Clin. Oncol. 22 2003 631 Abstract No: 2538
137. Rudin C.M. Otterson G.A. Mauer A.M. et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann. Oncol. 13 2002 539-545
138. Franklin W.A. Veve R. Hirsch F.R. et al. Epidermal growth factor receptor family in lung cancer and premalignancy Semin. Oncol. 29 2002 3-14
139. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin. Oncol. 29 2002 3-9
140. Cerny T. Barnes D.M. Hasleton P. et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours Br. J. Cancer 54 1986 265-269
141. Potti A. Willardson J. Forseen C. et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma Lung Cancer 36 2002 257-261
142. Micke P. Hengstler J.G. Ros R. et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis Int. J. Cancer 92 2001 474-479
143. Coudert B. Anthoney A. Fiedler W. et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report Eur. J. Cancer 37 2001 2194-2198
144. Wistuba I.I. Gazdar A.F. Minna J.D. Molecular genetics in small cell lung cancer Semin. Oncol. 28 2001 3-13
145. Arteaga C.L. Khuri F. Krystal G. Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer Semin. Oncol. 29 2002 15-26
146. Micke P. Basrai M. Faldum A. et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications Clin. Cancer Res. 9 2003 188-194
147. Wang W.L. Healy M.E. Sattler M. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 Oncogene 19 2000 3521-3528
148. Johnson B.E. Fischer T. Fischer B. et al. Phase II study of imatinib in patients with small cell lung cancer Clin. Cancer Res. 9 2003 5880-5887
149. Sattler M. Salgia R. Molecular and cellular biology of small cell lung cancer Semin. Oncol. 30 2003 57-71
150. Carney D.N. Biology of small-cell lung cancer The Lancet 339 1992 843-846
151. Kaye F.J. Molecular biology of lung cancer Lung Cancer 34 2001 S35-S41
152. Rodriques-Salas N. Palacios J. Moreno G. et al. Correlation of p53 oncoprotein expression with chemotherapy responde in small cell lung carcinomas Lung Cancer 34 2001 67-74
153. Hege K.M. Carbone D.P. Lung cancer vaccines and gene therapy Lung Cancer 41 2003 S103-S113
154. Murray N. Salgia R. Fossella F.V. Targeted molecules in small cell lung cancer Semin. Oncol. 31 2004 106-111
155. Fossella F.V. Tolcher A. Elliott M. et al. Phase I trial of the monoclonal antibody conjugate, BB-10901, for replapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors Proc. Am. Soc. Clin. Oncol. 21 2002 309a
156. Tolcher A. Forouzesh B. McCreery H. et al. A phase I and pharmacokinetic study of BB10901, a maytansinoid immunoconjugate, in CD56 expressing tumors Eur. J. Cancer 38 Suppl 7 2002 S152
157. Cancer.gov. Phase I/II study of BB-10901 in patients with recurrent or refractory small cell lung cancer, other pulmonary tumours of neuroendocrine origin, non-pulmonary small cell carcinoma, metastatic carcinoid tumor, or other CD56+ solid tumors. National Cancer Institure, Bethesda 2003 [Updated 2003 November 20; cited 2004 April 12]. Available from http://www.cancer.gov/clinicaltrials/ BBIO-C10/IVB/001
158. Chute J.P. Venzon D.J. Hankins L. et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute Mayo Clin. Proc. 72 1997 901-912
159. Lassen U.N. Hirsch F.R. Osterlind K. et al. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer 20 1998 151-160
160. Plunkett T.A. Chrystal K.F. Harper P.G. Quality of life and the treatment of advanced lung cancer Clin. Lung Cancer 5 2003 28-32